Renal Denervation for Hypertension Management: Past, Current Evidence and Future Directions

Clicks: 20
ID: 328917
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #34 of 80 articles by views in American Journal of Hypertension

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Hypertension remains the most prevalent modifiable cardiovascular risk factor worldwide, and continues to account for substantial morbidity, mortality, and health care burden despite established pharmacologic and lifestyle-based therapies. Poor long-term adherence, therapeutic inertia, polypharmacy, and persistent implementation gaps have generated interest in device-based therapies that provide durable BP reduction, independent of daily medication use. Renal denervation (RDN) has emerged as the most extensively studied catheter-based intervention targeting the sympathetic pathways that contribute to blood pressure regulation. This review summarizes the physiological basis for RDN, including the role of efferent and afferent renal sympathetic pathways in the development and maintenance of hypertension. We review the evolution of RDN technology from first-generation radiofrequency systems to multielectrode radiofrequency, ultrasound-based, and alcohol-mediated platforms, with attention to procedural refinements and lesion patterns over time. We then examine the clinical evidence across major trials, from early open-label studies to modern sham-controlled programs, which now consistently demonstrate modest but clinically meaningful reductions in ambulatory and office BP with an acceptable safety profile in selected patients. Beyond BP lowering, renal denervation may have broader biologic effects on cardiac remodeling, neurohormonal activation, inflammation, arrhythmias, metabolic dysfunction, and cardiorenal pathways, although these data remain preliminary, without any evidence from outcome studies. Important knowledge gaps persist, particularly the absence of cardiovascular outcomes trials, variability in treatment response, and the need for improved phenotyping to identify likely responders. As technology, patient selection, and mechanistic understanding continue to advance, RDN may become an increasingly important adjunct in the management of uncontrolled hypertension.
Reference Key
openalex_W7213422220 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shahzad Hassan, Iliana Hurtado Rendon, Nikolaos Spilias, Laura Bredel, Yiannis Chatzizisis, Maria Delgado-Lelievre
Journal American Journal of Hypertension
Year 2026
DOI
10.1093/ajh/hpag112
URL
https://doi.org/10.1093/ajh/hpag112
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.